Who are metformin\pioglitazone\exenatide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-pioglitazone-exenatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

metformin\pioglitazone\exenatide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

metformin\pioglitazone\exenatide (metformin\pioglitazone\exenatide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist). Area: Diabetes.

marketed Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist) Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin\pioglitazone\exenatide (metformin\pioglitazone\exenatide) — The University of Texas Health Science Center at San Antonio. This triple-agent combination improves blood glucose control through three complementary mechanisms: metformin reduces hepatic glucose production, pioglitazone increases insulin sensitivity in muscle and fat, and exenatide stimulates insulin secretion in response to glucose.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metformin\pioglitazone\exenatide TARGET	metformin\pioglitazone\exenatide	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist)	Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist) class)

The University of Texas Health Science Center at San Antonio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin\pioglitazone\exenatide — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-pioglitazone-exenatide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab